Familial Chylomicronemia Syndrome Market
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by a mutation in lipoprotein lipase. Lipoprotein lipase is a digestive enzyme in the blood that helps the body break down chylomicrons. People with FCS are either unable to make lipoprotein lipase or have a broken form.
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market" target="_blank" rel="noopener noreferrer">Familial Chylomicronemia Syndrome&nbsp; Market</a> Insight (2022)
<ul>
<li>The Familial Chylomicronemia Syndrome Market size in the 7MM was valued ~USD 15 million in 2022 </li>
<li>WAYLIVRA (volanesorsen), the only approved drug in Europe, covered the highest market size in the 7MM.</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-epidemiology" target="_blank" rel="noopener noreferrer">Familial Chylomicronemia Syndrome&nbsp; Epidemiology</a> Insights (2022)
The Familial Chylomicronemia Syndrome Diagnosed prevalent cases in the 7MM were ~2K cases in 2022
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-pipeline-insight" target="_blank" rel="noopener noreferrer">Familial Chylomicronemia Syndrome Emerging Drugs</a> and Key Companies
<ul>
<li>Olezarsen: Ionis Pharmaceuticals</li>
<li>ARO-APOC3: Arrowhead Pharmaceuticals, Inc., and others</li>
</ul>

Familial Chylomicronemia Syndrome Market

Familial Chylomicronemia Syndrome Market Infographics

Familial Chylomicronemia Syndrome Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.